Literature DB >> 11736698

Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium.

J O Karlsson1, H Brurok, M Eriksen, R Towart, K G Toft, O Moen, B Engebretsen, P Jynge, H Refsum.   

Abstract

PURPOSE: To evaluate whether manganese dipyridoxyl diphosphate (MnDPDP) or its metabolite manganese dipyridoxyl ethyldiamine (MnPLED) reduces post-ischemic myocardial injury.
MATERIAL AND METHODS: Left anterior descending artery (LAD) in anesthetized pigs was occluded (30 min) followed by reperfusion (120 min) during hemodynamic monitoring and infarct assessment. Three micromol/kg MnDPDP, 1 micromol/kg MnPLED (or a mixture of both) or saline was injected i.v. 10 min before reperfusion followed by infusion of either 3 micromol/kg/h MnDPDP, 1 micromol/kg/h MnPLED (or a mixture of both) or saline. The plasma concentrations of MnDPDP, MnPLED and other metabolites (e.g., ZnDPDP and ZnPLED) were analyzed.
RESULTS: Femoral blood flow was reduced by 60% during early reperfusion in controls, whereas only 23 and 31% reductions were seen in animals treated with MnDPDP and MnPLED. During that time, +LV/dP and -LV/dP (maximum rate of left ventricular isovolumic contraction and relaxation, respectively), systolic pressure and diastolic pressure fell significantly less in animals treated with MnDPDP or MnPLED. Three out of 5 control animals experienced ventricular fibrillation (VF) during reperfusion, whereas VF was not seen in any of the pigs treated with MnPLED or/and MnDPDP. The infarct sizes in saline- and MnPLED-treated animals were 39+/-6 and 16+/-5%, respectively, of the occluded areas. MnDPDP did not reduce the infarct size. A mixture of MnDPDP and MnPLED significantly reduced infarct size (10+/-4%). When reperfusion started and throughout reperfusion, almost all injected MnDPDP was present as Zn-metabolites.
CONCLUSION: MnPLED seems to reduce reperfusion-induced cardiac dysfunction and infarct size in pigs. MnDPDP does not reduce infarct size in the pig, probably because of the rapid exchange of Mn2+ for Zn2+ taking place in the pig.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736698     DOI: 10.1080/028418501127347340

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.701


  6 in total

1.  Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir.

Authors:  Romain Coriat; Jérôme Alexandre; Carole Nicco; Laurent Quinquis; Evelyne Benoit; Christiane Chéreau; Hervé Lemaréchal; Olivier Mir; Didier Borderie; Jean-Marc Tréluyer; Bernard Weill; Joel Coste; François Goldwasser; Frédéric Batteux
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

2.  First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study.

Authors:  Jan Olof G Karlsson; Karin Adolfsson; Bo Thelin; Per Jynge; Rolf Gg Andersson; Ursula G Falkmer
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

3.  Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.

Authors:  Tino Kurz; Derek Grant; Rolf Gg Andersson; Robertson Towart; Michelandrea De Cesare; Jan Olof G Karlsson
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

4.  Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct.

Authors:  Jan Olof G Karlsson; Tino Kurz; Susanne Flechsig; Jacques Näsström; Rolf Gg Andersson
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

5.  Pretreatment with mangafodipir improves liver graft tolerance to ischemia/reperfusion injury in rat.

Authors:  Ismail Ben Mosbah; Yann Mouchel; Julie Pajaud; Catherine Ribault; Catherine Lucas; Alexis Laurent; Karim Boudjema; Fabrice Morel; Anne Corlu; Philippe Compagnon
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 6.  MnDPDP: Contrast Agent for Imaging and Protection of Viable Tissue.

Authors:  Per Jynge; Arne M Skjold; Ursula Falkmer; Rolf G G Andersson; John G Seland; Morten Bruvold; Viggo Blomlie; Willy Eidsaunet; Jan O G Karlsson
Journal:  Contrast Media Mol Imaging       Date:  2020-09-04       Impact factor: 3.161

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.